Deal of the Day — limited-time pharmacy picks!
Votrient 400mg Tablet

Votrient 400mg Tablet

Prescription requiredRx Required

Salt Composition: Pazopanib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

30 tablet

About The Product

  • Advanced Renal Cell Carcinoma (RCC)
  • Soft Tissue Sarcoma (STS)
  • Soft tissue sarcoma (a tumor that develops in the muscles, joints, organs, tendons, or blood vessels) and kidney cancer (renal cell carcinoma) are treated with Votrient 400mg tablets.
  • Pazopanib 400mg is found in Votrient Tablets, which are administered after other therapies have failed. Pazopanib is a member of the class of tyrosine kinase inhibitors.

Uses

  • Advanced Renal Cell Carcinoma (RCC)
  • Soft Tissue Sarcoma (STS)

Side Effects

Votrient 400mg tablet has several side effects, which are given below. If the below-mentioned symptoms are seen in the patients and are not tolerable, immediately consult the doctor.

  • Bleeding risks
  • Headache
  • Breathing problem
  • Pain in the bone, joints & muscles
  • Change in taste
  • Hair color change
  • Skin pigmentation 
  • Low appetite
  • Irregular heartbeat
  • Vomiting
  • Diarrhea
  • Fatigue
  • Nausea
  • Hypertension 
  • Increased sugar levels
  • Hepatotoxicity

How To Use

  • You have to follow the doctor's prescription strictly for better results.
  • Swallow it as a whole.
  • Do not chew, crush, or break it.
  • Votrient 400mg Tablet is to be taken on an empty stomach.


How It Works

  • Votrient (pazopanib) 400 mg works by blocking certain proteins called tyrosine kinases that help tumors grow new blood vessels.
  • By inhibiting these pathways, it reduces blood supply to the tumor, slowing its growth and spread.

Safety Advice

Alcohol
The safety of consuming alcohol while taking Votrient 400mg Tablet has not been established, so it is advisable to consult your doctor.
Pregnancy
Do not take​ the Votrient 400mg tablet without consulting the doctor in case of pregnancy. There is clear evidence that using Votrient 400mg Tablets during pregnancy causes a risk to the growing baby.
Breast Feeding
Using Votrient 400mg Tablets during breastfeeding is not advised. Evidence suggests the medicine's potential to be hazardous to the newborn child.
Driving
It is not advisable to drive or operate heavy machinery; you may feel dizzy as one of the side effects of the medicine.
Kidney
Do not take ​the Votrient 400mg tablet without a doctor's consultation in case of kidney problems.
Liver
Share your medical history with the doctor in case of liver disease before taking this medicine.

Missed Doses

  • ​In case you missed any dose, consult your doctor.
  • Swallow Votrient 400 mg whole on an empty stomach; do not chew, crush, or break the tablet.
  • Do not take twice the dose to catch up on the missed dose. This will cause severe side effects and impact your overall health.​

FAQs

Votrient 400mg tablet is used to treat advanced kidney cancer and advanced soft tissue sarcomas.


References

  • Kwon, J. H., Lee, S. E., Choi, J. Y., Kim, H. Y., & Park, S. H. (2024). Real-world outcomes of pazopanib in advanced soft tissue sarcoma: A multicenter study in Korea. Cancer Medicine, 13(5), 2173–2182 - https://pubmed.ncbi.nlm.nih.gov/32607656/
  • Ravaud, A., Motzer, R. J., & Sternberg, C. N. (2023). Long-term safety of pazopanib in advanced renal cell carcinoma: A pooled analysis of clinical trial data. Clinical Genitourinary Cancer, 21(2), e137–e145.
  • Singh, A., Mehra, N., & Kapoor, A. (2023). Comparative safety and efficacy of pazopanib versus sunitinib in metastatic renal cell carcinoma: A meta-analysis. Journal of Oncology Pharmacy Practice, 29(4), 301–309 - https://pubmed.ncbi.nlm.nih.gov/39257075/
  • Tan, A. R., Weiss, G. J., Bilen, M. A., Sonpavde, G., & George, S. (2023). Pharmacokinetics and exposure–response relationship of pazopanib in patients with renal cell carcinoma and sarcoma. Clinical Pharmacokinetics, 62(3), 347–358.
  • Van Der Graaf, W. T., Gelderblom, H., & Mathijssen, R. H. J. (2024). Does individualization of pazopanib in soft tissue sarcoma: The case for therapeutic drug monitoring? European Journal of Cancer, 190, 1–9.
  • Verheijen, R. B., Lolkema, M. P. J., de Bruijn, P., et al. (2024). Optimizing pazopanib dosing: Evaluation of reduced-dose strategies in oncology patients. British Journal of Clinical Pharmacology, 90(2), 389–400 - https://pmc.ncbi.nlm.nih.gov/articles/PMC5595974/

Certified Content

Written By
Venika Choudhary

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By
Dr. Aditya Sarin

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026